Sequential IgG antibody monitoring for virusinactivated and adenovirusvectored COVID19 vaccine in Brazilian health care workers
J. med. virol
; 94(8): 3714-3721, Apr. 2022. graf, tab
Article
in En
| CONASS, SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1368540
Responsible library:
BR79.1
ABSTRACT
Vaccination certainly is the best way to fight against the COVID19 pandemic. In this study, the seroconversion effectiveness of two vaccines against severe acute respiratory syndrome coronavirus 2 was assessed in healthcare workers virusinactivated CoronaVac (CV, n= 303), and adenovirusvectored OxfordAstraZeneca (AZ, n= 447). The immunoglobulin G (IgG) antibodies antispike glycoprotein and antinucleocapsid protein were assessed by enzymelinked immunosorbent assay at the time before vaccination (T1), before the second dose (T2), and 30 days after the second dose (T3). Of all individuals vaccinated with AZ, 100% (n= 447) exhibited seroconversion, compared to 91% (n= 276) that were given CV vaccine. Among individuals who did not respond to the CV, only three individuals showed a significant increase in the antibody level 4 months later the booster dose. A lower seroconversion rate was observed in elders immunized with the CV vaccine probably due to the natural immune senescence, or peculiarity of this vaccine. The AZ vaccine induced a higher humoral response; however, more common side effects were also observed. Nonvaccinated convalescent individuals revealed a similar rate of antispike IgG to individuals that were given two doses of CV vaccine, which suggests that only a oneshot COVID19 vaccine could produce an effective immune response in convalescents.
Full text:
1
Collection:
06-national
/
BR
Database:
CONASS
/
SES-SP
/
SESSP-IDPCPROD
Main subject:
Glycoproteins
/
SARS-CoV-2
Country/Region as subject:
America do sul
/
Brasil
Language:
En
Journal:
J. med. virol
Year:
2022
Document type:
Article